(Q35103048)

6 August 2017

1 reference

title

Heparin and low molecular weight heparin: background and pharmacology (English)

1 reference

6 August 2017

1 reference

1 reference

Timothy A Morris

1

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Clinics in Chest Medicine

6 August 2017

published in

1 reference

6 August 2017

volume

24

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

39-47

1 reference

Actions and Interactions of Antithrombin and Heparin

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

1 reference

7 January 2021

Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Mobile reactive centre of serpins and the control of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

The separation of active and inactive forms of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Biochemistry and Physiology of Blood Coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Role of Thrombin Compared With Factor Xa in the Procoagulant Activity of Whole Blood Clots

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

The regulation of natural anticoagulant pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

D-dimer testing and acute venous thromboembolism. A shortcut to accurate diagnosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Diagnostic and prognostic value of fibrinopeptides in patients with clinically suspected pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Diagnostic Value of Fibrinopeptide A and Beta-Thromboglobulin in Acute Deep Venous Thrombosis and Pulmonary Embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900053-9

7 January 2021

10.1016/S0272-5231(02)00053-9

Identifiers

DOI

1 reference

6 August 2017

1 reference